CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. held its 2026 Annual Meeting of Shareholders on May 5, 2026. Shareholders approved the 2026 Long-Term Incentive Plan, which had been previously adopted by the Board of Directors. Additionally, twelve directors were elected to serve until the 2027 Annual Meeting, executive officer compensation was approved on an advisory basis, and the appointment of PricewaterhouseCoopers LLP as independent auditors for fiscal 2026 was ratified.

Charles River Laboratories International, Inc. reported a net loss of $14.8 million, or $(0.30) diluted EPS, for the first quarter of 2026, a significant decline from a net income of $25.9 million in the prior year. Total revenue saw a modest increase to $995.8 million. The company completed the acquisition of a Cambodian NHP supplier for $507.3 million and PathoQuest SAS, while also divesting its CDMO and Cell Solutions businesses, which resulted in a pre-tax loss of $118.0 million. Additionally, an agreement to sell certain European Discovery Services businesses for $145.0 million is in progress.

Charles River Laboratories reported first-quarter 2026 revenue of $995.8 million, a 1.2% increase year-over-year. The company posted a GAAP diluted loss per share of $(0.30), primarily due to a $118.0 million loss on assets held for sale related to the recently completed divestiture of its CDMO and Cell Solutions businesses. Non-GAAP diluted earnings per share decreased 12.0% to $2.06. The company reaffirmed its 2026 organic revenue and non-GAAP EPS guidance and repurchased $200 million of common stock during the quarter.